Assessing Parkinson’s Gait via Smartphone Video and AI

Original Title: Deep learning-enabled accurate assessment of gait impairments in Parkinson's disease using smartphone videos

Journal: NPJ digital medicine

DOI: 10.1038/s41746-025-02150-8

Overview

Parkinson's disease affects millions globally, with gait impairments serving as a primary source of disability. Traditional assessment relies on the Unified Parkinson’s Disease Rating Scale, which is often subjective and lacks the sensitivity to detect minor changes. This study introduces a deep learning framework that utilizes videos recorded by a single smartphone from lateral perspectives to evaluate gait. The system employs a Siamese contrastive network architecture to fuse information from both sides of the body. In testing, the model achieved a micro-average area under the receiver operating characteristic curve of 0.87 and an F1 score of 0.806 for predicting disease severity. These results are comparable to the performance of three clinical specialists, who showed an average error rate of 0.19 versus the model's 0.20. Furthermore, the framework identified medication-induced changes with 73.68% precision. It successfully detected subtle improvements in patients whose clinical scores remained unchanged, demonstrating a higher resolution than standard rating scales.

Novelty

The technical contribution lies in the design of a Siamese contrastive network that integrates dual-perspective lateral videos, allowing for a comprehensive analysis of bilateral symmetry and gait dynamics. Unlike previous methods that often rely on frontal views or multiple fixed cameras, this approach uses a single mobile device. The researchers implemented a modification algorithm to correct leg keypoint misidentifications that occur when limbs cross in lateral footage. Another distinct feature is the interpretability provided by a dual maximum gradient-weighted class activation mapping method. This allowed the extraction of both traditional markers, such as arm swing amplitude (correlation of -0.64), and novel digital biomarkers. Specifically, the average linear velocity of the ankle emerged as a highly sensitive indicator with a correlation of -0.66 to disease severity. The study also introduced a fine-granular assessment score that integrates predicted probabilities and confidence levels to identify medication responses that fall between the coarse increments of clinical scales.

Potential Clinical / Research Applications

This technology facilitates objective, longitudinal monitoring of Parkinson's disease in domestic environments, reducing the need for frequent hospital visits. In clinical research, the framework can serve as a sensitive tool for evaluating the efficacy of new disease-modifying therapies, potentially detecting therapeutic signals that traditional scales might miss. The identification of specific biomarkers, such as neck and head acceleration, allows for personalized medication adjustments based on individual motor responses. Beyond Parkinson's disease, the methodology could be adapted to assess motor impairments in other neurological conditions, including stroke recovery and Alzheimer's disease. The availability of a simplified online assessment system further lowers the barrier for clinical adoption and data collection across diverse populations.

Similar Posts

  • A metasurface combined with a neural network enables simultaneous detection of frequency, polarization, and intensity for broadband terahertz light.

    Original Title: Deep learning-enabled ultra-broadband terahertz high-dimensional photodetector Journal: Nature communications DOI: 10.1038/s41467-025-63364-8 A Deep Learning-Powered THz Photodetector Overview Light carries information in multiple forms, including its intensity, frequency (color), and polarization. Conventional photodetectors typically measure only a subset of these properties, limiting our ability to fully characterize a light field. This paper introduces a compact photodetector that overcomes this limitation in the terahertz (THz) frequency range. It combines a specially engineered metasurface with a deep learning algorithm to simultaneously and continuously measure the intensity, full polarization state, and frequency of incident light across a broad spectrum from 0.3 to 1.1 THz. Novelty The device’s innovation lies in its method…

  • Caregiver Views on AI-Based Dementia Screening Tools

    Original Title: Dementia Care Research and Psychosocial Factors Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association DOI: 10.1002/alz70858_099304 Overview This study investigates caregiver perspectives on the dementia diagnostic process and the introduction of artificial intelligence (AI) technologies. Current pathways rely on pen-and-paper assessments and informant reports, which are often perceived as insufficient or overly simplistic. Researchers recruited 13 caregivers for a two-stage qualitative assessment to evaluate these existing methods against emerging digital alternatives. The first stage involved semi-structured interviews regarding the memory assessment pathway and the extent of caregiver involvement. The second stage used a think-aloud protocol where participants compared traditional tools, like the Cambridge Behavioural Inventory,…

  • Multimodal AI for Epileptiform Discharge Detection

    Original Title: Development and validation of a multimodal automatic interictal epileptiform discharge detection model: a prospective multi-center study Journal: BMC medicine DOI: 10.1186/s12916-025-04316-3 Overview Researchers developed and tested a deep learning model, vEpiNetV2, to automatically detect interictal epileptiform discharges (IEDs), which are key biomarkers for epilepsy. The model is multimodal, meaning it analyzes both electroencephalogram (EEG) brainwave data and synchronized video recordings of the patient. It was trained on data from 530 patients at one hospital. The model’s performance was then prospectively evaluated on new, independent datasets from three different medical centers, including a children's hospital, totaling 377 hours of recordings from 149 patients. The results showed consistent performance across…

  • AI Model to Predict Gout Recurrence in Hospitalized Patients

    Original Title: Development and validation of a multidimensional and interpretable artificial intelligence model to predict gout recurrence in hospitalised patients: a real-world, ambispective multicentre cohort study in China Journal: BMC medicine DOI: 10.1186/s12916-025-04454-8 Overview Researchers addressed the challenge of predicting gout recurrence in hospitalized patients with other health conditions. This large, multicentre study in China included 6,526 patients in both retrospective and prospective cohorts. Using 82 clinical, laboratory, and medication features, the team developed and rigorously tested 3,744 different artificial intelligence models to find the most accurate and reliable one. The final selected model, a Gradient Boosting algorithm, demonstrated good predictive performance. It achieved an area under the curve (AUC)…

  • WeChat-Based AI Agent for Postoperative Orthopedic Care

    Original Title: A randomized controlled trial of a WeChat-based artificial intelligence agent for postoperative care in orthopedic patients Journal: NPJ digital medicine DOI: 10.1038/s41746-025-02269-8 Overview This randomized controlled trial evaluated a GPT-4-powered artificial intelligence agent delivered via the WeChat platform to support postoperative recovery in orthopedic patients. The study included 261 participants, with 140 assigned to the AI-driven intervention and 121 to traditional physician-led communication. Effective postoperative management is often hindered by limited access to timely support and poor adherence to rehabilitation protocols. The AI system demonstrated a significantly faster response time of 0.5 ± 0.6 minutes compared to 358 ± 47.5 minutes in the doctor-led group (p < 0.05)….

  • A study of 691 FDA-cleared AI/ML devices reveals significant reporting gaps in efficacy, safety, and bias, calling for better regulation.

    Original Title: Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence-Enabled Medical Devices Journal: JAMA health forum DOI: 10.1001/jamahealthforum.2025.3351 FDA AI/ML Device Reporting Lacks Transparency Overview A comprehensive analysis of 691 artificial intelligence and machine learning (AI/ML) medical devices cleared by the US Food and Drug Administration (FDA) between 1995 and 2023 reveals significant deficiencies in benefit-risk reporting. The cross-sectional study examined FDA decision summaries and postmarket surveillance databases. It found that crucial information was frequently missing. For instance, 95.5% of device summaries lacked demographic data for the populations on which the AI was tested, 53.3% did not report the training sample size, and 46.7% omitted the study design. The evidence supporting clearance…

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA